TNF and ulcerative colitis: Although vedolizumab, a gut-selective α4β7 integrin antagonist, is associated with a lower risk of systemic infections compared to anti-TNF agents [17,18,21,22], its localized impact on mucosal immunity may still predispose patients to enteric infections, particularly in ulcerative colitis.